Clippings

Experimental integrase inhibitor GSK-572 shows continued promise

Date: 23-07-2010

The second-generation integrase inhibitor S/GSK1349572, or GSK-572 for short, continues to demonstrate potent antiviral activity - including activity against HIV strains resistant to raltegravir (Isentress) - as it prepares to enter Phase III clinical trials, according to two studies presented this week at the Eighteenth International AIDS Conference in Vienna. SPRING-1 Laboratory and early clinical studies showed that

Click here to read full story provided by NAM

Go back to clippings list.